purchased assets from BioMicro
Systems for all products associated with the Roche
NimbleGen microarray workflow. These assets include the NimbleGen Hybridization Systems (both 4- and 12-bay models) and array accessories covering all mixers designed for the Roche NimbleGen high-density microarray portfolio.
With the purchase of these assets, Roche Diagnostics will transfer the manufacturing capabilities for the above products to an in-house manufacturing facility. “The acquired products are integral to the high-quality data the NimbleGen array workflow provides researchers worldwide,” points out Andreas Görtz, vp of marketing at Roche NimbleGen.